ReviewFrontiers in endocrinology2025
Diabetes and brain: omics approaches to study diabetic encephalopathy.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Buwang Formula Regulates Microglial Metabolic Reprogramming and Modulates the mTOR/HIF-1α Pathway to Reduce Neuroinflammation in Diabetic Mice.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Relationship of Estimated Glomerular Filtration Rate (eGFR) and Neuron-Specific Enolase (NSE) with Cognitive Dysfunction in Type 2 Diabetes Mellitus: A Cross-Sectional Analysis.International journal of general medicine · 2026Article
- Panax-derived ginsenosides in diabetes-associated cognitive dysfunction: mechanistic evidence and translational barriers.Frontiers in endocrinology · 2026Review
- β‑hydroxybutyric acid as a potential therapeutic metabolite for type 2 diabetes mellitus (Review).International journal of molecular medicine · 2026Review
- A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a complex metabolic disorder associated with many complications, including diabetic encephalopathy (DE). DE is a severe neurological condition characterized by a progressive decline in cognitive and motor functions, significantly impacting patients' quality of life. Despite advancements in understanding DM, the intricate pathogenetic mechanisms underlying DE remain incompletely elucidated. This review comprehensively analyzes the application of omics technologies to decipher the molecular basis of DE and identify potential diagnostic biomarkers and therapeutic targets. Several studies on animal models of DE have revealed specific metabolic signatures and changes in gene expression in key memory brain regions, like the hippocampus, highlighting potential therapeutic targets. We explore how these "omics" approaches have provided novel insights into the complex interplay of factors contributing to DE. Recurrent alterations were identified upon evaluation of analysis from human tissues and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.